Navigation Links
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Date:10/10/2007

BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, today announced that it has appointed William T. Poncy, M.B.A., as vice president of commercial development. Mr. Poncy will direct the commercial launch of Ketasyn (AC-1202) as a medical food product in the U.S. for the treatment of Alzheimer's disease.

"Given his strong track record in all aspects pharmaceutical commercialization, we are thrilled to welcome Bill to our management team," commented Steve Orndorff, Ph.D., president and CEO. "We are confident that his strong track record combined with Ketasyn's excellent safety and efficacy will allow Accera to make a competitive entry into the multi billion-dollar Alzheimer's market."

Additionally, Mr. Poncy will be responsible for developing Accera's neurodegenerative disease franchise for ethical drugs now in development for Parkinson's disease, Huntington's disease, and age-associated memory impairment.

With more than 25 years of experience in the pharmaceutical industry, Mr. Poncy most recently served as vice president of sales and marketing at Myogen, Inc. (now Gilead Sciences), where he built the commercial organization and launched a pulmonary anti-hypertension franchise. Previously he was the North American vice president of sales and marketing for Pharmion Corp., where he developed an oncology commercial organization. He has also held positions in sales, managed care, trade, marketing and various management roles at DuPont Pharmaceuticals and Berlex Labs.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease (AD) and age-associated me
'/>"/>

SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Research and Markets has ... Microcrystalline Cellulose Industry Report 2014" report to their ... Cellulose Industry Report 2014 is a professional and in-depth ... cellulose industry with a focus on the Chinese situation. ... the industry including definitions, classifications, applications and industry chain ...
(Date:9/22/2014)... and TORONTO , Sept. ... www.generex.com ) (OTCBB:GNBT) today announced that it has ... (UHN) pursuant to which UHN,s Centre for Molecular ... buccal insulin refinement project.  The goal of the ... Generex Oral-lyn™, the Company,s proprietary buccal insulin spray ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... Md., Sept. 2 Micromet, Inc.,(Nasdaq: MITI ... novel, proprietary antibodies for the treatment of cancer,inflammation ... A. Phillips as Senior Vice President and Chief ... of the Company,s board of directors,since 2000, and ...
... a New Jersey-based,leading provider of prescription co-pay programs ... significantly expanded the scope of,the lawsuit that it ... the State,of New York, County of New York, ... of McKesson Corporation. PSKW is,now seeking, in addition ...
... The BEAUTIFUL study: a step further in title ... BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular ... among patients with stable coronary ... dysfunction, ESC Hotline ...
Cached Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 3
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... have come up with a new twist in their efforts ... DNA genetic code. They have developed the first, versatile DNA ... key to unlocking the vital code behind human heredity and ... director of the Biodesign Institute,s Center for Single Molecule Biophysics, ...
... 2010) For years, doctors have warned patients to finish ... "superbug" that can mount a more powerful defense against the ... engineers indicates that treating bacteria with levels of antibiotics insufficient ... wide range of antibiotics. In the Feb. 12 issue ...
... help save the sight of patients with a type of ... University of Leeds found that the TSPAN12 gene is faulty ... Vitreoretinopathy), which affects the development of the eye. While ... of the same family may carry the faulty gene without ...
Cached Biology News:ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 2ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 3Low levels of antibiotics cause multidrug resistance in 'superbugs' 2Low levels of antibiotics cause multidrug resistance in 'superbugs' 3New gene discovery could help to prevent blindness 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: